Toys, insurance and shower toilets

tonies, Straumann, Moderna, Steyr Motors, UNIQA, Talanx, Carlsberg, Geberit, Implenia, NEPI Rockcastle, Bucher Industries, Emmi

Toys, insurance and shower toilets

At Lux Opes, we break down companies into quick takes that get straight to the point - what is happening, why it matters, and what to watch next. We publish 2-3 times per week, depending on the news flow.

For the best reading experience, we recommend reading at Lux Opes

Financial KPIs

Companies covered in this edition: tonies, Straumann, Moderna, Steyr Motors, UNIQA, Talanx, Carlsberg, Geberit, Implenia, NEPI Rockcastle, Bucher Industries, Emmi

Raw data from Bloomberg; may contain inaccuracies. Full width in browser

tonies (TNIE Germany): The boxes are in homes, now the figurines have to follow

● NEUTRAL

Toniebox sales lifted revenue 41% in H1, but the margin fell to 0.7% and the full-year target needs a big second half.

Tonies sold a lot of hardware in the spring, and the first-half accounts show both the reward and the cost. Revenue rose 38% to €242.9m, or 41% in constant currency, and the second quarter alone grew 48% to €117.3m. Tonieboxes grew 75% in the quarter to €31.8m, helped by a weak base because retailers held back orders a year ago ahead of the Toniebox 2 launch. The figurines, which carry the margin, grew 41% to €81.7m in the quarter and 32% to €177.1m over the half. Boxes now account for 24% of half-year revenue, up from 20% a year earlier.

That shift in mix went straight into the gross line. Cost of goods rose from 29.1% to 35.7% of revenue, gross profit after licensing fell from 58.8% to 53.1%, and US tariffs landed at an awkward moment. Fulfilment, marketing and overheads all fell as a share of revenue, but not by enough, so adjusted EBITDA came in at €1.8m, a 0.7% margin against 2.1% a year ago. Free cash flow was minus €64.3m because the company is building stock for the Bluey, Pokémon and Hasbro launches and for Toniebox Lite.

North America is now the biggest market and the fastest growing one. Revenue there rose 57% in constant currency to €104.3m in the half, and 85% to €56.5m in the second quarter, so the region now brings in 43% of group sales. The segment earned an EBITDA margin of 1.3%, though, while DACH earned 24.4%, up 7.9 points, on €88.9m of revenue. DACH shows what an installed base is worth once households keep buying figurines for years. North America is still at the stage where tonies pays to put the boxes in place.

The guidance asks a lot of the second half. More than €760m of revenue means at least €517m between July and December, at least 14% above the same period of 2025, and a 9% to 11% adjusted EBITDA margin means €68m to €84m of EBITDA, or a second-half margin of roughly 13% to 16% after 0.7% in the first. Management says most revenue and profit always come late in the year, and the content line-up is the strongest in years. The risk we would watch is Toniebox Lite. It is a cheaper second device launching in exactly the half in which the mix has to swing back towards figurines, so a strong Lite launch could repeat the margin squeeze of the spring at the worst possible time.


Straumann (STMN Switzerland): A strong hand to pass to a new CEO

● POSITIVE

Organic growth reached 8.5% in Q2 with North America back above 8%; Christopher Norbye takes over as CEO in December.

Guillaume Daniellot is leaving Straumann on a good quarter. The company announced with its half-year figures that he will step down after nearly 20 years at the group, seven of them as CEO, and that Christopher Norbye takes over on 1 December. Second-quarter revenue reached CHF 707.0m, 8.5% higher organically and 5.9% higher in francs, and the half came to CHF 1,379.5m with 7.8% organic growth. The franc took most of the difference: in Swiss francs the half grew only 2.3%.

North America is the change that counts. Organic growth there was 8.4% in the second quarter, against 2.7% in the same quarter of 2025, even though patient flow was broadly flat and consumers cautious. The company credits iEXCEL, which already makes up close to 40% of Straumann premium implant volumes, and dental service organizations. EMEA grew 8.6%, with Poland and Hungary strong, and Latin America 11.8%. Asia Pacific grew 7.4%, but 25.0% excluding China, where patient flow recovered only gradually and the second round of volume-based procurement may start its process in the second half, with execution early in 2027.

Profitability improved underneath the currency noise. Core EBIT was CHF 354.8m, a 25.7% margin as reported and 26.9% at 2025 exchange rates, so currency cost about 1.2 points. Core operating costs fell by roughly 130 basis points as a share of revenue. The guidance raised in June stands: high single-digit organic growth and core EBIT margin expansion of 140 to 170 basis points at constant rates, spread evenly over both halves. Free cash flow rose 49% to CHF 168.6m as capital spending came down after the capacity build. Two items sit outside the core figures: CHF 21.6m of income, mostly tariff refunds, and CHF 18.0m of legal costs in the US dispute with Align, where a jury found neither side liable in June.

Norbye inherits a business with growth in every region and margins moving the right way. The open points are outside his control in the near term: how hard VBP 2.0 hits Chinese pricing and how much the franc keeps eating. The one thing we would watch is the first set of targets under the new CEO, because a reset of the 2027 ambitions would change the reading of what is currently a clean run of upgrades.


Moderna (MRNA US): The cancer result it needed, with the cash bill still running

● POSITIVE

Personalised mRNA therapy beat Keytruda alone in phase 3 melanoma; Moderna still burns about $1bn in the second half.

Moderna finally has a phase 3 win outside respiratory vaccines. With Merck it reported that intismeran autogene, its individualised neoantigen therapy, combined with Keytruda met the primary endpoint of recurrence-free survival in INTerpath-001, a study in patients with completely resected stage IIB to IV melanoma. Distant metastasis-free survival, a secondary endpoint, was also met at the prespecified interim analysis, and the safety profile showed nothing new. Overall survival will be assessed in later readouts, and the data go to a medical meeting and to regulators. The two companies describe it as the first phase 3 study showing a clinically meaningful gain for a combination over pembrolizumab alone, which is standard adjuvant care in this setting.

The size of the benefit has not been published. The best guide is the phase 2b KEYNOTE-942 study, whose five-year update at ASCO this year showed a 49% lower risk of recurrence or death (hazard ratio 0.51) and a 59% lower risk of distant metastasis or death. The hazard ratio that comes out at the medical meeting will matter more than the headline. Each treatment is designed from the mutations of the patient's own tumour, which makes production a per-patient job, very different from a seasonal vaccine run.

The pipeline behind it is wide. Moderna and Merck have nine phase 2 and phase 3 trials running across melanoma, non-small cell lung cancer, bladder and kidney cancer, including a phase 3 in high-risk stage 1 lung cancer started last quarter. The same quarter brought a setback elsewhere: the norovirus vaccine mRNA-1403 missed the bar for early success at its phase 3 interim look, and the company now has to enrol another cohort.

The financial picture explains why this readout matters so much. Second-quarter revenue was $145m against research and development spending of $651m, about 4.5 times revenue. Cash and investments were $6.9bn at the end of June, a $950m litigation payment followed in July, and the year-end target is $4.7bn to $5.2bn. That leaves roughly $0.75bn to $1.25bn of cash use in the second half excluding the settlement. A melanoma approval would not change that in 2026 or 2027, and the product is shared with Merck. What the result does change is the probability that the oncology spend produces revenue at all, and that was the biggest doubt about the company.


Steyr Motors (4X0 Austria): Built for orders that have not arrived

● VERY NEGATIVE

Defence delays cut 2026 revenue guidance to €56-61m, cash fell to €0.3m and the 2027 targets were dropped.

Steyr Motors expanded for a defence ramp-up that slipped. On 17 August the board cut its 2026 revenue guidance to €56m to €61m, 15% to 25% above the €48.5m of 2025, from €75m to €95m before, and lowered the EBIT margin target to 8% to 12% from at least 15%. The 2027 targets of about €140m of revenue and €40m of EBIT were withdrawn. The reason given is slow procurement, approval and acceptance on international defence projects: about €10m of revenue planned for the first half did not happen, will probably not be caught up this year, and more delays cannot be ruled out. Management says the demand is intact and the revenue is moving out by one to two years, which according to the CFO pushes the old 2027 level to 2029 at the latest.

The half-year accounts show how exposed the company is when volumes stall. Revenue was €22.8m, against €23.1m a year earlier. Reported EBIT swung to a loss of €1.1m from a €3.4m profit, and the €0.1m adjusted EBIT needs €1.14m of items removed, including restructuring, legal and advisory costs, share options and the BUKH acquisition. Military revenue fell 30.2% to €9.4m. Civil marine grew 38.5% to €13.4m, but €1.87m of that came from BUKH, the Danish marine engine maker consolidated from April, so the existing civil business grew about 19%. Staff rose from 121 to 151 full-time equivalents.

The balance sheet worries us more than the income statement. Cash fell from €7.3m at the start of the year to €0.3m at the end of June, operating cash flow was minus €4.7m and inventory rose from €17.1m to €26.4m, of which €5.5m came with BUKH. Bank debt went from zero to €5.7m and reverse factoring from €8.3m to €9.9m. A company carrying stock for delayed orders has very little room left.

The cut guidance is still demanding. It implies €33m to €38m of revenue in the second half, 31% to 50% more than the €25.4m of the second half of 2025, and EBIT of roughly €4.4m to €7.2m after break-even in the first half. Even on 2025 earnings, before the cut, the group is on 21.5x 2025 EV/EBITDA and 29.3x 2025 P/E, a rating built for the 2027 plan that has now been withdrawn.

The order backlog of more than €310m runs to 2030 and includes auxiliary power units for around 500 Leopard 2 tanks under a KNDS framework deal to 2034, a US Navy tender for 474 boats specified with Steyr engines and 1,000 vehicles for a Spanish customer from 2027. The delayed projects named include a Polish defence ministry tank program, locomotive engines for Siemens in Scandinavia and an engineering project in India. A backlog stretching to 2030 is not cash, and until deliveries resume Steyr is financing growth it cannot yet bill.


UNIQA (UQA Austria): Markets carried the half while underwriting slipped

● NEUTRAL

Investment income rose 47% and lifted pre-tax profit 10.5%, while the technical result fell despite few natural disasters.

UNIQA's higher first-half profit came from the stock market. Earnings before taxes rose 10.5% to €326.5m. Net investment income rose 46.7% to €586.7m and the financial result doubled to €176.4m, while the insurance service result, the technical line, fell 4.9% to €359.9m. Management points to positive equity performance in the second quarter.

Growth itself was strong. Premiums written, including savings portions, rose 12.0% to €4,924.2m, with property and casualty up 16.2%. Insurance revenue grew 7.9% to €3,773.8m: property and casualty 6.2%, health 11.7% and life 10.2%, with Austria up 7.9% and the international companies up 6.2%. The problem sits in the cost lines. Health insurance service expenses rose 12.8%, ahead of health revenue, and life expenses rose 14.4% against 10.2% revenue growth. The reinsurance service result worsened from minus €54.7m to minus €88.1m. The net combined ratio rose to 91.6% from 90.5%, and the CEO himself notes that the half benefited from a low burden from natural disasters. A weaker combined ratio in a calm catastrophe period is the detail we would not ignore.

The guidance looks deliberately cautious. UNIQA kept its target of €540m to €570m of pre-tax profit, of which 57% to 60% is already in the bag. That leaves €213.5m to €243.5m for the second half, 25% to 35% below the first, so the target effectively assumes the investment gains do not repeat. Solvency stayed at 271%, the contractual service margin, the stock of future profit on existing business, rose 7.4% to €6.3bn, and the dividend payout target remains 50% to 60%. The CEO says the focus for the rest of the year is strengthening core underwriting, with profitability and efficiency in Austria and growth above GDP in Central and Eastern Europe. The capital base is not the issue. Whether the technical margin recovers is, because that is the part of the profit that repeats.


Talanx (TLX Germany): A record half with help from the loss budget

● POSITIVE

Net income rose 9% to €1.5bn and guidance went up, helped by large losses €474m under budget.

Talanx raised its outlook after a record first half, and the main reason is that the year has been kind to insurers so far. Group net income rose 9% to €1,499m. Large losses came to €942m against a pro rata budget of €1,416m, which was booked in full, so claims ran €474m below plan. That covered a €200m reserve in reinsurance for possible losses from the Iran war. The combined ratio improved to 88.7% from 90.7%. The investment result rose 21% to €1,025m as the group keeps rolling low-yield bonds into higher-yield ones, and return on equity was 21.5%.

The new guidance is for net income of significantly more than €2.7bn, with a return on equity of about 19%. Doubling the first half gives about €3.0bn, while a €2.7bn result would need only €1.2bn in the second half, 20% less than the first. That gap is room for a normal hurricane season, and it makes the upgrade a cautious one. At 10.6x 2026e P/E and 10.1x 2027e for a group guiding to a c.19% RoE, the rating gives little credit for this year's benign losses, which is the right starting point when reinsurance pricing is softening.

Primary insurance, the business outside Hannover Re, contributed 52% of group profit and grew its net income 12%. Retail International did the growing: revenue rose 10% in constant currency to €5.1bn, led by Poland, Türkiye and Mexico, EBIT rose 17% to €616m and the investment result climbed 23% to €292m on larger books in Poland and Türkiye, though the combined ratio edged up to 91.2%. Corporate & Specialty revenue held at €5.0bn because of currency and more careful underwriting of new business, but large losses of €92m were €209m under budget and the combined ratio improved to 90.7%. Retail Germany lost revenue after the Targobank partnership expired at the end of 2025, its combined ratio rose to 93.0% on higher large losses, and EBIT still rose 37% to €180m thanks to cost savings.

The reinsurance side shows where the cycle is going. Property and casualty reinsurance revenue fell 4% in constant currency to €8.8bn, even with a combined ratio of 83.2%, while life and health reinsurance grew 12%. Solvency rose to 246% from 224% a year earlier. Talanx is earning very well, but growth in commercial lines is slowing as pricing softens, and a good part of this half's margin came from losses that did not happen. We would not extrapolate the 88.7% combined ratio.


Carlsberg (CARLB Denmark): Soft drinks and synergies do the growing

● POSITIVE

Organic profit rose 5.9% while beer volumes fell; faster Britvic synergies narrowed guidance to 4-6% growth.

Carlsberg's first half was a soft-drinks half. Organic volumes grew 1.7%, but beer volumes fell 1.0%, mainly in Poland, China and Ukraine, while soft drinks, alcohol-free beer and other drinks grew 7.8%. Soft drinks were up 9% organically, alcohol-free brews 11% and Pepsi 17%, against 1% for premium beer. Revenue rose 2.6% to DKK 47,053m, with 2.7% organic growth and revenue per hectolitre up 1% overall. Operating profit grew 5.9% organically and 4.5% as reported to DKK 7,448m, and the margin rose 30 basis points to 15.8%.

By region the picture is uneven. Central & Eastern Europe and India grew volumes 6.2%, Western Europe 0.1% and Asia not at all, with poor weather in China dragging on sales. Western Europe, where Britvic sits, still improved its operating margin by 80 basis points to 13.8%, which is where the integration shows up most clearly. Management narrowed guidance to 4% to 6% organic operating profit growth from 2% to 6%, on a 2025 base of DKK 13,686m, so roughly DKK 14.2bn to DKK 14.5bn before currency. The main reason is Britvic: Carlsberg now expects about 50% of the targeted £110m of synergies this year, around £55m, against 30% to 40%, or £33m to £44m, before. That brings forward £11m to £22m of savings into 2026. The CEO also points to cost discipline and performance management, plus a partnership with Sapporo in premium beer and a wider PepsiCo deal covering the Nordics, the Baltics and Azerbaijan.

Cash flow is moving the right way. Free operating cash flow rose 27% to DKK 3,694m, and net debt to EBITDA came down to 3.0x. The target is 2.5x, to be reached with free cash flow, a hybrid bond and the proceeds from Sapporo's investment in the new joint venture. The weak spot is the core product. A brewer whose beer volumes are shrinking depends on soft drinks and on synergy timing for its profit growth, and synergies are a one-off source. Once the £110m is in the numbers, beer has to grow again or the margin story runs out.


Geberit (GEBN Switzerland): Volumes are back, but material costs keep the margin flat

● POSITIVE

Local-currency sales rose 5.9% in H1 on volumes and price, yet EBITDA margin stayed at 30.9% as material costs jumped.

Geberit is growing volumes again, and it is doing so without much help from the market. Net sales rose 5.9% in local currencies in the first half and 2.8% in francs to CHF 1,711m, and the pace picked up clearly from 3.4% in the first quarter. The company puts the growth down to significant volume gains plus price increases, across regions and all three product areas. Switzerland grew almost 10% organically and Europe as a whole 5.6%.

Very little of that reached the margin. EBITDA rose 3.0% to CHF 529m and the margin stayed at 30.9%, and in the second quarter it slipped to 29.4% from 30.1%. Volume and price helped, and one-off costs from last year dropped out, but direct material costs rose sharply, wages went up and Geberit spent more on marketing, IT and digitalisation. Net income still grew 7.4% to CHF 364m and earnings per share 7.9% to CHF 11.09, or 10.9% before currency, because buybacks keep reducing the share count. The CEO thinks raw material prices have peaked for now and expects them to move sideways in the third quarter compared with the second.

The full-year guidance is 5% to 6% growth in local currencies with an EBITDA margin around last year's 29.4%. According to the CEO, about 2.5 points of that come from the price increases made in the first half, so volume growth for the year works out at roughly 2.5% to 3.5%, below the first-half pace. He expects volumes to slow in the second half, partly because the second half of 2025 was strong. In Europe Geberit sees slight market growth but no broad recovery yet, with new residential building turning positive as permits rise. Outside Europe, India is improving while new construction in China falls.

Shareholders are getting the cash. A CHF 300m buyback finished in early June and a new CHF 300m program has started, which took net debt to CHF 1.33bn, while free cash flow fell 12.1% to CHF 217m on higher investment and the timing of tax payments. The new program is c.1.6% of a CHF 19.3bn market cap, bought back on 29.7x 2026e P/E and 21.6x 2026e EV/EBITDA, so buybacks add little to EPS and volume has to carry the growth. The operating trend is better than at any point in the last few years. The limit is the cost side: as long as material prices stay high, extra volume buys stable margins and little more.


Implenia (IMPN Switzerland): Less revenue, a fuller order book and better margins

● POSITIVE

EBIT rose 6% on lower revenue, the order book grew 9.6% to CHF 8.5bn, and the second half carries the target.

Implenia keeps doing less work at better prices. First-half revenue fell 4.8% to CHF 1,767m, yet EBIT rose 6.0% to CHF 60.4m and the margin improved to 3.4% from 3.1%. The order book grew 9.6% to CHF 8,524m, about 2.4 times the CHF 3.5bn of revenue booked in 2025, and the margin calculated into those projects at signing rose to 7.9% from 7.5%. That pre-calculated margin is the number to follow, because it shows what the company should earn once the new work is being built.

The divisions tell a more mixed story. Buildings earned CHF 37.5m, down from CHF 41.5m, because real estate development contributed CHF 14.0m against CHF 20.8m, while construction improved to CHF 23.5m. Its order book rose 17% to CHF 3,010m on an extra fit-out order at a data centre already under construction and wins in German defence and education buildings. Civil Engineering lifted EBIT to CHF 18.8m even though revenue fell to CHF 926m from CHF 1,008m, which management blames on the slow early phases of large infrastructure projects; its order book reached CHF 5,445m, with a cost-plus project in Gothenburg and four large bridges in Germany and Norway. Service Solutions earned CHF 11.7m on CHF 121m of revenue, a 9.7% margin against 7.6% a year earlier, and is adding the German engineering firm zigmo.

Cash discipline also improved. The seasonal free cash outflow narrowed to CHF 118m from CHF 168m, the equity ratio rose to 23.4% from 21.3%, and the full CHF 400m of syndicated credit lines was undrawn. Headcount fell 5.2% to 8,152. The target for 2026 is EBIT of about CHF 150m before CHF 10m to CHF 20m of extra growth spending, most of which lands in the second half on teams for data centres, healthcare and life sciences buildings in Germany and western Switzerland and for defence work. On that basis the second half has to deliver about CHF 90m before those costs, half as much again as the first. From 2027 the company expects more than CHF 150m, and in the medium term up to CHF 1bn of extra revenue at a 4.5% margin. The backlog quality supports that path. What is missing is revenue growth, and the 4.5% margin will not come from cost savings alone.


NEPI Rockcastle (NRP Netherlands): Steady rent growth and a first step west

● POSITIVE

DEPS rose 3.5% and guidance was raised to 3.5-4%; the Bilbao purchase is the first deal outside Central and Eastern Europe.

NEPI Rockcastle raised its guidance, but the upgrade is modest. Distributable earnings per share rose 3.5% to 32.14 euro cents in the first half, and the board now expects 3.5% to 4% growth for the year on the 62.03 cents of 2025, against roughly 3% before. That means 64.2 to 64.5 cents for the year and 32.1 to 32.4 cents in the second half, 3.5% to 4.5% above the second half of 2025. Like-for-like property performance added 1.83 cents and the solar business 0.22 cents, more than offsetting higher taxes and financing costs. The interim dividend is 28.93 cents, a 90% payout.

The shopping centres are doing what they should. Like-for-like net operating income rose 3.3% to €312m on indexation, short-term income and better service charge recovery, which reached 96% even though operating costs rose 7.6%, mostly on utilities. Footfall was flat at minus 0.4%, but the average basket rose 3.3% and like-for-like tenant sales 2.7%, led by health and beauty and services while furnishings, sports goods and electronics fell. The occupancy cost ratio stayed at 13.2%, occupancy at 98.2%, and new leases and renewals were signed 3% above indexation. Renewable energy produced a €5.7m net result, up 38%.

Values and the balance sheet moved in step. The portfolio gained €126m, 1.6% like-for-like, to €8.4bn, and EPRA net tangible assets rose to €7.86 per share from €7.64 in December. That puts the stock at c.1.0x EPRA NTA, and the guided 64.2 to 64.5 cents of distributable earnings is a c.8.1% earnings yield at 33.1% LTV. Loan-to-value edged up to 33.1%, under the 35% ceiling, S&P upgraded the company to BBB+ in July and liquidity stood at €1.2bn before a new €250m EBRD green loan.

The real news is the Bilbao deal. NEPI agreed to buy MegaPark Barakaldo for €252m, about 3% of the portfolio and its first investment in Spain or anywhere in Western Europe, closing by the end of September, while Ozas in Vilnius is held for sale. Development spending stays heavy, with €162m planned for the second half and Promenada Bucharest's extension, 95% let, opening in April 2027. Leaving the region where it has scale is a strategic change, and one asset without a local platform carries more execution risk than another extension in Bucharest. The deal is small enough to absorb, but we would want to know whether it is the start of a series before treating it as a side note.


Bucher Industries (BUCN Switzerland): The farm cycle still sets the pace

● NEGATIVE

Kuhn orders fell 21% and Bucher cut its 2026 outlook; four other divisions took more orders.

Bucher lowered its outlook for 2026 on 30 July and now expects slightly lower sales on a comparable basis and an operating margin below last year's level excluding the CHF 43m property gain of 2025. Stripped of that gain, last year's margin was about 8.2%. The first half shows why the bar came down. Order intake fell 3.8% to CHF 1,241m, sales 4.3% to CHF 1,471m and EBIT 41% to CHF 105m, a 7.1% margin. Part of the drop is the missing property profit, but even excluding it, first-half EBIT fell by about a fifth, from an 8.8% margin to 7.1%. Bucher Vaslin added CHF 8m of restructuring costs.

Kuhn Group, the farm machinery business and 42% of first-half sales, is the problem. Orders fell 21% to CHF 329m after dealers had ordered heavily in the second half of 2025. Farmers face low prices for arable crops, sharply higher fertiliser and diesel costs, worries about fertiliser supply, poor weather and political uncertainty, and in Brazil high interest rates on top. Sales still rose 2.6% on a comparable basis thanks to the order book, but the margin fell to 8.8% from 9.9%, mainly because of severe under-utilisation in Brazil. The order book is down 10.5% to CHF 229m, and Kuhn only expects stable sales this year.

The rest of the group took more orders. Bucher Hydraulics grew orders 4.8% and comparable sales 7.5%, with construction machinery and electric drives in demand and China and India growing, and lifted its margin to 10.8%. Municipal orders rose 5%, though sales fell 6% from a thin starting order book. Emhart Glass took 7% more orders, but its sales dropped 26% and the margin fell to 5.0% from 13.4% on very low plant utilisation. Bucher Specials lost money on the wine-equipment business, and Bucher Automation will be split between Emhart Glass and Hydraulics from 2027.

Order intake covered only 84% of sales in the half, so the second half starts with less work in hand. The balance sheet can carry a long wait, with CHF 278m of net cash and a 66% equity ratio, and a new CEO, Matthias Kümmerle, has been in place since April. A recovery needs farm investment in Europe and Brazil to turn, and nothing in this report suggests that is close.


Emmi (EMMN Switzerland): The cash is in, the profit target leans on the second half

● POSITIVE

Organic growth of 3.6% was all volume and EBIT rose 4.8%; guidance needs a much bigger second half.

All of Emmi's growth came from volume. Organic sales rose 3.6% in the first half, while currencies took 2.1% and acquisitions added 0.7%, for reported sales of CHF 2,323.5m, up 2.2%. Gross margin improved to 40.8% from 40.0% thanks to purchasing, productivity and price increases, but operating costs rose 4.9% to CHF 724.2m on personnel and logistics, so EBIT grew 4.8% to CHF 152.3m, a 6.6% margin. Net profit rose a slower 3.7% to CHF 100.9m because minority shareholders in Brazil, Mexico and Chile took CHF 12.3m, almost double last year's CHF 6.7m.

Switzerland grew 3.6% despite a lower milk reference price, but the number flatters: a fixed-term contract added 2.0 points and will stop in the second half, while lower milk prices cost 1.1 points, so the underlying figure was 2.7%. Americas grew 3.6% organically, driven by Chile, Brazil, Mexico, Spain and Tunisia, while the US fell short as consumers held back. Europe grew 2.7% organically with desserts and Dutch goat milk powder, but Emmi Caffè Latte disappointed in much of Europe apart from Belgium. Global Trade grew 10.1% on butter and milk powder exports. The four premium niches, nutrition+, ready-to-drink coffee, premium desserts and specialty cheese, make up around 40% of sales and grew well above average, with nutrition+ at double digits.

The outlook was raised for sales and held for profit. Organic growth is now expected at 2% to 3%, EBIT at CHF 335m to CHF 355m and the net margin at 4.8% to 5.3%. The milk price and the end of the contract will cut second-half growth by about 1.9%, and 4.7% in Switzerland, after helping the first half by 0.4%. EBIT of CHF 335m to CHF 355m needs CHF 183m to CHF 203m in the second half, 20% to 33% more than in the first, while reported growth slows.

Cash is the strongest part of the report. Operating cash flow rose 21% to CHF 202.6m, 88% of EBITDA against 75% a year ago, and net debt fell to 1.73 times EBITDA from 1.79 despite the dividend. Return on invested capital improved to 7.9%, which is still well short of the 10% mid-term target. Emmi is executing well, but the gap to that target is large, and a second half that has to earn a third more than the first leaves little room for another soft spell in the US.